Pharmaceutical company Lekhim PrJSC (Kyiv) plans to appoint Crowe Erfolg Ukraine LLC as the auditor of the company and consolidated financial statements of its subsidiaries (Lekhim Group of Pharmaceutical Companies) for 2024 and 2025.
As the company reported in the information disclosure system of the National Securities and Stock Market Commission (NSSMC), the shareholders will consider such a proposal of the board of directors of the company at a meeting on December 27.
As reported, in 2023, Lekhim reduced its net profit by 4.3 times compared to 2022 to UAH 56.929 million.
The Lekhim Group of Companies includes Lekhim-Obukhiv LLC, Lekhim Kharkiv PrJSC, Technolog (Cherkasy region), and Lekhim-Vilnius CJSC.
Lekhim produces more than 200 medicinal products of almost all therapeutic groups. It registers more than 10 new drugs annually. The products are exported to more than 35 countries. One of Lekhim’s anti-tuberculosis drugs has been prequalified by the WHO.
Crowe Erfolg Ukraine is a member of Crowe Global, one of the world’s largest audit networks.
